Recent breakthroughs in understanding the molecular mechanisms underlying NSCLC have enabled the development of targeted therapies, including those directed at epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, and the incorporation of immune-checkpoint inhibitors (ICI). Here, ALK is linked to non-small cell lung carcinoma.